Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > AstraZeneca opens biomethane plant in UK to cut emissions
    Finance

    AstraZeneca opens biomethane plant in UK to cut emissions

    Published by Global Banking & Finance Review®

    Posted on February 27, 2025

    2 min read

    Last updated: January 25, 2026

    AstraZeneca opens biomethane plant in UK to cut emissions - Finance news and analysis from Global Banking & Finance Review
    Tags:sustainabilityrenewable energyinnovation

    Quick Summary

    AstraZeneca launches a UK biomethane plant to power its operations with renewable energy, aiming for net zero emissions by 2045.

    AstraZeneca Launches Biomethane Facility in the UK to Reduce Emissions

    By Maggie Fick

    LONDON (Reuters) - AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its research and development and drug manufacturing in Britain is powered by clean energy, it said on Thursday.

    The plant, operated through a 15-year agreement between AstraZeneca and UK-based biomethane producer Future Biogas, will supply 100 gigawatt hours (GW) of renewable energy per year for AstraZeneca's three R&D and manufacturing sites in the country, equivalent to 20% of its total gas consumption globally.

    WHY IT’S IMPORTANT

    Many big companies have been dropping commitments to cutting emissions and switching to renewable energy as cost-cutting has become a major priority and U.S. President Donald Trump's return to the White House has shifted the focus to fossil fuels.

    In Britain, Prime Minister Keir Starmer's government is pushing to decarbonise the country's power network with the help of private investment.

    AstraZeneca's new plant in Lincolnshire, eastern England, is not subsidised by the UK government.

    The company says its switch to renewable energy in the UK is part of a broader commitment to use 100% renewable energy for all of its own operations globally by the end of this year.

    Its commitment to a goal of net zero emissions by 2045, which it set in 2020, also depends on its suppliers using green power.

    CONTEXT

    AstraZeneca entered a similar long-term agreement in 2023 with a U.S. company, Vanguard Renewables, that enabled it to transition to biogas from natural gas and cut its emissions across its U.S. research and manufacturing sites.

    The company aims to reduce greenhouse gas emissions it directly produces by 98% by 2026, from a 2015 baseline.

    Though Danish drugmaker Novo Nordisk has set similar targets to reduce its carbon footprint, it said earlier this month that its emissions grew 23% in 2024 and will keep rising through the end of the decade as it boosts production of its blockbuster obesity drug Wegovy.

    (Reporting by Maggie Fick; editing by Barbara Lewis)

    Key Takeaways

    • •AstraZeneca opens a biomethane plant in the UK.
    • •The plant will power UK R&D and manufacturing with clean energy.
    • •The facility is part of AstraZeneca's net zero by 2045 goal.
    • •The UK plant operates without government subsidies.
    • •AstraZeneca's global operations aim for 100% renewable energy by 2023.

    Frequently Asked Questions about AstraZeneca opens biomethane plant in UK to cut emissions

    1What is the purpose of AstraZeneca's new biomethane plant?

    The plant is designed to produce biogas from organic waste, ensuring that AstraZeneca's research and development and drug manufacturing in the UK will use renewable energy.

    2How much renewable energy will the plant supply?

    The plant will supply 100 gigawatt hours (GW) of renewable energy per year for AstraZeneca's UK operations.

    3What are AstraZeneca's sustainability goals?

    AstraZeneca aims to use 100% renewable energy for all its operations globally by the end of this year and has set a goal of net zero emissions by 2045.

    4Is the new plant subsidized by the UK government?

    No, AstraZeneca's new plant in Lincolnshire is not subsidised by the UK government.

    5What other agreements has AstraZeneca made regarding renewable energy?

    In 2023, AstraZeneca entered a long-term agreement with Vanguard Renewables in the U.S. to transition to biogas from natural gas, aiming to reduce emissions across its U.S. operations.

    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostAviva beats profit estimates as insurance premiums soar
    Next Finance PostInsurer Ageas expects European market to outperform Asia business in 2025